FST.L Regulatory News (FST)

11 Apr 2008 09:10

Nanoscience Inc11 April 2008 For Immediate Release Nanoscience Inc. ('Nanoscience' or the 'Group') Toumaz Technology As Part of Consortium That Wins €7.1 million European Community Grant Nanoscience, the specialist niche investor in emerging technologies with strongcommercial propositions for the healthcare and electronic sectors, is pleased toannounce that its wholly-owned subsidiary Toumaz Technology Limited ('Toumaz'),is part of a major collaborative research project that has been awarded a €7.1million grant to fund the development of a portable blood glucose predictorsystem for diabetes patients. The Personal Glucose Predictive Diabetes Advisor ('DIAdvisorTM') system is aunique personalised blood glucose prediction tool that allows patients at anytime to actively and accurately predict their short-term blood glucose outlookby the analysis of data retrieved from glucose measurements, insulin deliverydata and specific patient parameters, which will be captured by non-intrusivebody-worn wireless monitors based on Toumaz's breakthrough SensiumTM platform. The grant award, made under the Seventh Framework Programme (FP7) of theEuropean Community, will fund the four-year research and development projectinto the DIAdvisorTM system. The large-scale project is being coordinated byNovo Nordisk A/S, a world leader in diabetes care, and will be delivered by aconsortium of 13 medical, industrial and academic partners, including theEuropean Division of the International Diabetes Federation. Toumaz's role in the project will be to implement the DIAdvisorTM hardware andsoftware platform, leverage the SensiumTM intelligent data acquisition platformand networking infrastructure to enable multiple vital signs measurements fromnon-intrusive body-worn monitors to be taken and merged with manually entered 'spot' measurements (such as food intake), providing the key data for thecreation of physiological mathematical modeling, control and predictionalgorithms. The resulting analysis and prediction information will then be ableto be wirelessly transmitted to a healthcare provider advisory service, withrecommended action and treatment advice presented to the patient via a handheldmobile device such as a Personal Digital Assistant (PDA). First stage data gathering and clinical trials are planned to start in August2008, with initial data expected by the end of the year. Dr Alison Burdett, Director of Technology for Toumaz commented: 'With DIAdvisorTM, we will be putting a sophisticated treatment advisor in thehands of patients for the first time, empowering them in their own healthcaremanagement and significantly reducing the likelihood of serious complicationsand recurrent hospitalisation due to poor glucose control. For healthcareproviders, DIAdvisorTM will have a significant positive impact on cost reductionfor the treatment of diabetes.' Guy Spelman CEO of Nanoscience commented: 'This is further good news from our investment in Toumaz and its development ofthe SensiumTM platform. Recognition of the growing importance of the SensiumTMplatform in more sectors in the field of medicine provides further evidence ofits versatility and increasing acceptance across global leaders and governmentbodies.' - Ends - About Toumaz Technology (www.toumaz.com) Toumaz Technology Limited is the leading provider of ultra-low power wirelessinfrastructure for body monitoring solutions. Toumaz's ultra low-power smartsensor interface and transceiver platform - the SensiumTM - enablesnon-intrusive, real-time wireless monitoring of multiple vital signs for a widerange of healthcare and lifestyle management applications. Based on Toumaz's patented ultra-low power Advanced Mixed Signal ('AMxTM')technology, the SensiumTM provides the enabling technology to connect the mobileindividual to healthcare providers - simply, affordably and unobtrusively. For healthcare professionals, this transforms the possibilities for pro-activemonitoring and improved quality of care. For patients, it delivers newopportunities for lifestyle-compatible, personalised healthcare, as well asbetter therapeutic outcomes. Further Information: Guy Spelman Nanoscience Inc. 07767 338 967 Vikki Krause Hansard Group 020 7245 1100 This information is provided by RNS The company news service from the London Stock Exchange